CN109288997A - A kind of compound medicine and its preparation method and application for treating rhinitis - Google Patents
A kind of compound medicine and its preparation method and application for treating rhinitis Download PDFInfo
- Publication number
- CN109288997A CN109288997A CN201811485928.8A CN201811485928A CN109288997A CN 109288997 A CN109288997 A CN 109288997A CN 201811485928 A CN201811485928 A CN 201811485928A CN 109288997 A CN109288997 A CN 109288997A
- Authority
- CN
- China
- Prior art keywords
- parts
- sodium
- extracting solution
- under reduced
- reduced pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 27
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 21
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 21
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 21
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 21
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 21
- 244000090896 Nigella sativa Species 0.000 claims abstract description 21
- 244000261559 Smilax china Species 0.000 claims abstract description 21
- 235000000485 Smilax china Nutrition 0.000 claims abstract description 21
- 240000009022 Smilax rotundifolia Species 0.000 claims abstract description 21
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims abstract description 21
- 235000008541 fennel flower Nutrition 0.000 claims abstract description 21
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 21
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 20
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 20
- 241001593750 Turcica Species 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 239000002674 ointment Substances 0.000 claims abstract description 14
- 239000007923 nasal drop Substances 0.000 claims abstract description 12
- 239000007921 spray Substances 0.000 claims abstract description 11
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 8
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 8
- 230000001684 chronic effect Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 74
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 239000000284 extract Substances 0.000 claims description 39
- 239000012141 concentrate Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 238000000605 extraction Methods 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 20
- 244000235603 Acacia catechu Species 0.000 claims description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
- 235000011187 glycerol Nutrition 0.000 claims description 17
- 239000008367 deionised water Substances 0.000 claims description 15
- 229910021641 deionized water Inorganic materials 0.000 claims description 15
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 13
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 13
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 13
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 13
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 13
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 13
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 11
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 11
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- 229960001631 carbomer Drugs 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- 239000001509 sodium citrate Substances 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 7
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 7
- 239000004299 sodium benzoate Substances 0.000 claims description 7
- 235000010234 sodium benzoate Nutrition 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 229910021538 borax Inorganic materials 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 239000004328 sodium tetraborate Substances 0.000 claims description 6
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 235000011083 sodium citrates Nutrition 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- -1 collunarium Substances 0.000 claims description 3
- 201000009240 nasopharyngitis Diseases 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 229960004274 stearic acid Drugs 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 239000003349 gelling agent Substances 0.000 abstract description 6
- 201000009151 chronic rhinitis Diseases 0.000 abstract description 4
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000000638 solvent extraction Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000080767 Areca catechu Species 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 19
- 238000003756 stirring Methods 0.000 description 18
- 238000000227 grinding Methods 0.000 description 15
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 241000208308 Coriandrum Species 0.000 description 11
- 235000002787 Coriandrum sativum Nutrition 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 238000012856 packing Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000008236 heating water Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- ZBZFFMBWUCAHIW-UHFFFAOYSA-L disodium propan-2-one sulfate Chemical compound [Na+].[Na+].CC(C)=O.[O-]S([O-])(=O)=O ZBZFFMBWUCAHIW-UHFFFAOYSA-L 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SRYLRVUJDQTFDL-UHFFFAOYSA-N 1-chloro-2,3,4-trinitrobenzene Chemical class [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1[N+]([O-])=O SRYLRVUJDQTFDL-UHFFFAOYSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DOBDNIISGNPFBO-UHFFFAOYSA-N C(C)O.[N+](=O)([O-])C1=C(C(=C(C=C1)Cl)[N+](=O)[O-])[N+](=O)[O-] Chemical compound C(C)O.[N+](=O)([O-])C1=C(C(=C(C=C1)Cl)[N+](=O)[O-])[N+](=O)[O-] DOBDNIISGNPFBO-UHFFFAOYSA-N 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Insects & Arthropods (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of rhinitis compound medicine and preparation methods and purposes, the compound medicine is made of chinaroot greenbrier, galla turcica, fennelflower seed, coptis root, peppermint, ceriander seed, 7 taste medicinal material of catechu, and nasal drop, spray, lotion, gelling agent or ointment is made using the methods of solvent extraction, removal of impurities, concentration, drying.The compound medicine is made according to national medical knowledge opinion in conjunction with modern study result.Pharmaceutical preparation of the present invention is simple, curative for effect, have no toxic side effect, dissolve out its effective component using reasonable drawing method, enhances drug effect, drug directly acts on schneiderian membrane, bioavilability is improved, preferably can be used to treat acute and chronic and allergic rhinitis, be provided convenience for patient.
Description
Technical field
The present invention relates to a kind of compound medicines and its preparation method and application for treating rhinitis, belong to national medicine technology neck
Domain.
Background technique
Rhinitis is intractable common disease, and global disease incidence is very high, involves the 5-50% of population, in China disease incidence 5-
15%.The systemic factor of its pathogenic factor and body, local factor, occupation is related with living environment, especially climate variability season
Disease incidence is more.With social progress, the rapid development of heavy industry etc., atmosphere pollution is aggravated, and makes the disease incidence of this disease year by year
Ascendant trend, it is especially pronounced over nearly more than 20 years.Doctor trained in Western medicine mainly uses antihistamine drug, nasmil, steroid hormone, subtracts at present
The therapies such as congested agent and the fiery desensitization of specific immunity desensitization, but it is big to eradicate difficulty, high recurrence rate and side effect.Uygur's medicine is recognized
For, rhinitis is that inside and outside disease factor can make body fluid unbalance and makings causes lung etc. to be declined by the natural force of dominating organs extremely,
To make abnormal phlegm be trapped in nasal cavity, schneiderian membrane is damaged, local blood circulation, which is obstructed, leads to rhinitis, clinically uses
Abnormal phlegm is removed, adjusts makings, cavity clearing ventilation, dehumidification swelling, convergence anti-inflammatory etc. is that basic principle is treated.In clinic
Using mature therapy, remove the treatment methods such as therapy, medicinal treatment.
Summary of the invention
Present invention aims at provide a kind of compound medicine and its preparation method and application for treating rhinitis, the compound medicine
Object is made of chinaroot greenbrier, galla turcica, fennelflower seed, coptis root, peppermint, ceriander seed, 7 taste medicinal material of catechu, using solvent extraction, removes
Nasal drop, spray, lotion, gelling agent or ointment is made in the methods of miscellaneous, concentration, dry.The compound medicine is cured according to nationality
Theory is made in conjunction with modern study result.Pharmaceutical preparation of the present invention is simple, curative for effect, have no toxic side effect, using reasonable
Extracting method dissolves out its effective component, enhances drug effect, and drug directly acts on schneiderian membrane, improves bioavilability, can be more
Good is used to treat acute and chronic and allergic rhinitis, provides convenience for patient.
A kind of compound medicine for treating rhinitis of the present invention, the compound medicine is using 1000ml as radix, by weight
Number is chinaroot greenbrier 5-80 parts, 5-60 parts of fennelflower seed, 5-60 parts of coptis root, 5-60 parts of peppermint, 5-60 parts of ceriander seed, galla turcica 5-80
Part, 5-60 parts of catechu, auxiliary material is glycerol, sodium carboxymethylcellulose, benzalkonium bromide, ethylparaben, sodium benzoate, citric acid
Sodium, sodium dihydrogen phosphate, sodium bicarbonate, azone, propylene glycol, borax or 5-37 parts of mannitol are made nasal drop, collunarium, are sprayed
Agent, ointment or gel preparation.
A kind of preparation method of compound medicine for treating rhinitis, follows these steps to carry out:
A, using 1000ml as radix will be in parts by weight 5-80 parts of chinaroot greenbrier, 5-60 parts of fennelflower seed, 5-60 parts of coptis root,
5-60 parts of peppermint, 5-60 parts of ceriander seed, 5-80 parts of galla turcica, 5-60 parts of catechu carry out being crushed to 10-20 mesh, are uniformly mixed, add
Entering 4-20 times of water or concentration is ethanol water refluxing extraction 1-4 times of 10-95%, and the time is 1-3 hours, merges and extracts
Liquid, then extracting solution is concentrated under reduced pressure, obtain concentrate；
B, the concentrate for obtaining step a is centrifuged 5-20 minutes, and centrifugal rotational speed is 5000-20000 revs/min；Or with dense
The ethanol solution that degree is 30-80% precipitates；Or stand, filtering obtains extracting solution；
C, it is glycerol, sodium carboxymethylcellulose, benzalkonium bromide, nipalgin second that auxiliary material, which is added, in the extracting solution for obtaining step b
Ester, sodium benzoate, carbomer, sodium citrate, sodium dihydrogen phosphate, carbomer, sodium bicarbonate, borax or 5-20 parts of mannitol mix
It closes uniformly, adjusting pH value is 5.5-7.5, and with deionized water constant volume, after sterilizing, routinely pharmaceutical methods are made nasal drop, wash nose
Agent, spray；
Or step b is obtained into extracting solution and is concentrated under reduced pressure, it is 50% that ethanol solution to concentration of alcohol, which is added, 24 hours are stood,
Filtrate is dried under reduced pressure into dry extract in the case where temperature is 55 DEG C, pressure is -0.08MPa by filtering, and addition auxiliary material is glycerol, carboxylic first
Base sodium cellulosate, benzalkonium bromide, ethylparaben, carbomer, stearic acid, glycerin monostearate, castor oil, sodium dihydrogen phosphate
Or 20-37 parts of sodium bicarbonate be uniformly mixed, adjustings pH value be 5.5-7.5, with deionized water constant volume, after sterilizing, routinely pharmacy
Ointment or gel preparation is made in method.
Or step b is obtained into extracting solution and is concentrated under reduced pressure, directly it is dried under reduced pressure in the case where temperature is 55 DEG C, pressure is -0.08MPa
At dry extract, addition auxiliary material is glycerol, sodium carboxymethylcellulose, benzalkonium bromide, ethylparaben, azone, propylene glycol, card wave
Nurse, stearic acid, glycerin monostearate, castor oil, sodium citrate, sodium dihydrogen phosphate or 20-37 parts of sodium bicarbonate are uniformly mixed,
Adjusting pH value is 5.5-7.5, and with deionized water constant volume, after sterilizing, routinely ointment or gel preparation is made in pharmaceutical methods.
The compound medicine of the treatment rhinitis is in preparation treatment acute rhinitis or/and rhinitis chronic and allergic rhinitis drug
In purposes.
Specific embodiment
Embodiment 1
It is radix system for nasal drop using 1000ml:
A, in parts by weight by 50 parts of the chinaroot greenbrier through having screened, 10 parts of fennelflower seed, 20 parts of coptis root, 30 parts of peppermint, coriander
5 parts of son, no 10 parts of 80 sub- parts, catechu co-grindings of food, cross 20 meshes, and water refluxing extraction 2 times of 20 times of amounts are added, extract every time
Time is 3 hours, combined extract, then extracting solution is concentrated under reduced pressure, and obtains concentrate；
B, it is 80% that ethanol solution to concentration of alcohol, which is added, in the concentrate for obtaining step a, stands 24 hours, and filtering obtains
To extracting solution；
C, it is 2 parts of sodium benzoate, 3 parts of glycerol that auxiliary material, which is added, in the extracting solution for obtaining step b, mixes, adds borax soln tune
Saving pH value is 5.5, with deionized water constant volume, is sterilized, packing, routinely nasal drop is made in pharmaceutical methods.
Embodiment 2
It is radix system for nasal drop using 1000ml:
A, in parts by weight by 80 parts of the chinaroot greenbrier through having screened, 60 parts of fennelflower seed, 10 parts of coptis root, 10 parts of peppermint, coriander
Sub 50 parts, 40 parts of 20 parts of galla turcica, catechu co-grindings, cross 10 meshes, and it is that 20% ethanol solution extracts 4 that 10 times of amount concentration, which are added,
Secondary, each extraction time is 1 hour, combined extract, then extracting solution is concentrated under reduced pressure, and obtains concentrate；
B, the concentration for obtaining step a stands 12 hours, and filtering obtains extracting solution；
C, the extracting solution for obtaining step b is added 3 parts of auxiliary material benzalkonium bromide, 4 parts of carbomer, mixes, adds sodium bicarbonate molten
It is 7.5 that liquid, which adjusts pH value, with deionized water constant volume, is sterilized, packing, routinely nasal drop is made in pharmaceutical methods.
Embodiment 3
It is radix system for nasal drop using 1000ml:
In parts by weight by 5 parts of the chinaroot greenbrier through having screened, 20 parts of fennelflower seed, 40 parts of coptis root, 30 parts of peppermint, ceriander seed 40
30 parts of part, 80 parts of galla turcica, catechu co-grindings cross 20 meshes, and it is that 40% ethanol solution extracts 3 times that 14 times of amount concentration, which are added,
Each extraction time is 2 hours, combined extract, then extracting solution is concentrated under reduced pressure, and obtains concentrate merging filtrate；
B, the concentrate for obtaining step a is centrifuged 5 minutes, and revolving speed is 20000 revs/min, and filtering obtains extracting solution；
C, the extracting solution for obtaining step b is added 5 parts of auxiliary material ethylparaben, 5 parts of sodium carboxymethylcellulose, mixes, adds
It is 6.5 that sodium dihydrogen phosphate, which adjusts pH value, with deionized water constant volume, is sterilized, packing, routinely collunarium is made in pharmaceutical methods
Agent.
Embodiment 4
It is radix system for collunarium using 1000ml
A, in parts by weight by 70 parts of the chinaroot greenbrier through having screened, 20 parts of fennelflower seed, 10 parts of coptis root, 15 parts of peppermint, coriander
Sub 30 parts, 20 parts of 40 parts of galla turcica, catechu co-grindings, cross 10 meshes, and the water that 18 times of amounts are added extracts 3 times, extraction time 3
Hour, combined extract, then extracting solution is concentrated under reduced pressure, obtain concentrate；
B, the ethanol solution that the concentrate concentration for obtaining step a is 30% precipitates, and stands 24 hours, and filtering obtains
Extracting solution；
C, 6 parts of auxiliary material benzalkonium bromide, 5 parts of glycerol is added in the extracting solution for obtaining step b, mixes, adds sodium bicarbonate solution
Adjusting pH value is 5.5, with deionized water constant volume, is sterilized, packing, routinely collunarium is made in pharmaceutical methods.
Embodiment 5
It is radix system for collunarium using 1000ml
A, in parts by weight by 20 parts of the chinaroot greenbrier through having screened, 50 parts of fennelflower seed, 40 parts of coptis root, 30 parts of peppermint, coriander
Sub 40 parts, 25 parts of 10 parts of galla turcica, catechu co-grindings, cross 10 meshes, and addition concentration is 70% ethanol water refluxing extraction 1
Secondary, extraction time is 2 hours, obtains extracting solution, then extracting solution is concentrated under reduced pressure, obtains concentrate；
B, the concentrate for obtaining step a, 5000 turns of revolving speed, is centrifuged 5 minutes, stands 12 hours, and filtering is extracted
Liquid；
C, 10 parts of auxiliary material sodium benzoate, 5 parts of glycerol is added in the extracting solution for obtaining step b, mixes, borax soln is added to adjust
PH value is 6.0, with deionized water constant volume, is sterilized, packing, routinely collunarium is made in pharmaceutical methods.
Embodiment 6
It is radix system for collunarium using 1000ml
A, in parts by weight by 30 parts of the chinaroot greenbrier through having screened, 5 parts of fennelflower seed, 50 parts of coptis root, 5 parts of peppermint, ceriander seed
35 parts, 60 parts of galla turcica, 40 parts of co-grindings of catechu to 10 mesh, the water that 18 times of amounts are added extract 2 times, and extraction time is 2 hours,
Combined extract, then extracting solution is concentrated under reduced pressure, obtain concentrate；
B, the concentrate for obtaining step a, revolving speed are 10000 revs/min, are centrifuged 20 minutes, and filtering obtains extracting solution；
C, 8 parts of auxiliary material ethylparaben, 7 parts of carbomer is added in the extracting solution for obtaining step b, mixes, adds sodium citrate
It is 7.0 that solution, which adjusts pH value, with deionized water constant volume, is sterilized, packing, routinely collunarium is made in pharmaceutical methods.
Embodiment 7
It is radix system for spray using 1000ml
A, in parts by weight by 35 parts of the chinaroot greenbrier through having screened, 15 parts of fennelflower seed, 20 parts of coptis root, 40 parts of peppermint, coriander
Sub 50 parts, 50 parts of 70 parts of galla turcica, catechu co-grindings, cross 10 meshes, and addition concentration is 30% ethanol water refluxing extraction 3
Secondary, extraction time is 1 hour, combined extract, then extracting solution is concentrated under reduced pressure, and obtains concentrate；
B, the concentrate for obtaining step a, revolving speed are 20000 revs/min, are centrifuged 10 minutes, and filtering obtains extracting solution；
C, 10 parts of auxiliary material benzalkonium bromide, 3 parts of glycerol is added in the extracting solution for obtaining step b, mixes, adds mannitol solution tune
Saving pH value is 5.8, with deionized water constant volume, is sterilized, packing, routinely spray is made in pharmaceutical methods.
Embodiment 8
It is radix system for spray using 1000ml
A, in parts by weight by 45 parts of the chinaroot greenbrier through having screened, 20 parts of fennelflower seed, 30 parts of coptis root, 50 parts of peppermint, coriander
Sub 5 parts, 40 parts of 50 parts of galla turcica, catechu co-grindings, cross 20 meshes, and the water that 10 times of amounts are added extracts 2 times, extraction time 2
Hour, combined extract, then extracting solution is concentrated under reduced pressure, obtain concentrate；
B, the ethanol solution that the concentrate concentration for obtaining step a is 50% precipitates, and stands 24 hours, and filtering obtains
Extracting solution；
C, 5 parts of auxiliary material sodium benzoate, 4 parts of glycerol is added in the extracting solution for obtaining step a, mixes, adds sodium bicarbonate solution
Adjusting pH value is 6.5, with deionized water constant volume, is sterilized, packing, routinely spray is made in pharmaceutical methods.
Embodiment 9
It is radix system for spray using 1000ml
A, in parts by weight by the chinaroot greenbrier 60 through having screened, 30 parts of fennelflower seed, 5 parts of coptis root, 10 parts of peppermint, ceriander seed 10
20 parts of part, 30 parts of galla turcica, catechu co-grindings cross 10 meshes, and the ethanol water refluxing extraction 2 that concentration is 50% is added
Secondary, extraction time is 3 hours, combined extract, then extracting solution is concentrated under reduced pressure, and obtains concentrate；
B, the concentrate for obtaining step a, revolving speed are 15000 revs/min, are centrifuged 15 minutes, and filtering obtains extracting solution；
C, 10 parts of auxiliary material benzalkonium bromide, 10 parts of carbomer is added in the extracting solution for obtaining step b, mixes, adds sodium citrate
It is 7.0 that solution, which adjusts pH value, with deionized water constant volume, is sterilized, packing, routinely spray is made in pharmaceutical methods.
Embodiment 10
It is radix system for ointment using 1000ml
A, in parts by weight by 10 parts of the chinaroot greenbrier through having screened, 60 parts of fennelflower seed, 20 parts of coptis root, 20 parts of peppermint, coriander
Sub 20 parts, 30 parts of 40 parts of galla turcica, catechu co-grindings, cross 10 meshes, and addition concentration is 80% ethanol water refluxing extraction 1
Secondary, extraction time is 3 hours, obtains extracting solution, then extracting solution is concentrated under reduced pressure, obtains concentrate；
B, the concentrate for obtaining step a, is precipitated with the ethanol solution that concentration is 80%, and filtering obtains extracting solution；
C, the extracting solution liquid pressurization concentration obtained step b, it is 50% that ethanol solution to concentration of alcohol, which is added, and it is small to stand 24
When, filtering, by concentrate temperature be 55 DEG C, pressure be -0.08MPa under be dried under reduced pressure into dry extract, be ground into fine powder, weigh
6 parts of auxiliary material stearic acid, 6 parts of glycerin monostearate and 2 parts of castor oil are co-located in dry beaker, and heating water bath makes to 70 DEG C
Quan Rong obtains matrix I, spare；10 parts of glycerol, 3 parts of ethylparaben, 10 parts of distilled water are set in another beaker, are heated to 70 DEG C,
Make complete molten, obtains matrix II, it is spare；Under stirring, matrix II is added in matrix I with thread shape, and in being kept in water-bath
Constant temperature is stirred continuously 3 minutes, is removed water-bath and continues to stir to room temperature, then obtained medicinal extract fine powder is added to ointment base
Zhi Zhong Subcommittee-to is even, is 6 with sodium bicarbonate tune pH value, sterilizing, routinely ointment is made in pharmaceutical methods.
Embodiment 11
It is radix system for ointment using 1000ml
A, in parts by weight by 75 parts of the chinaroot greenbrier through having screened, 5 parts of fennelflower seed, 40 parts of coptis root, 5 parts of peppermint, ceriander seed
30 parts, 40 parts of 20 parts of galla turcica, catechu co-grindings cross 20 meshes, and the water that 16 times of amounts are added extracts 2 times, and extraction time is 1 small
When, combined extract, then extracting solution is concentrated under reduced pressure, obtain concentrate；
B, the concentrate for obtaining step a, revolving speed are 20000 revs/min, are centrifuged 5 minutes, and filtering obtains extracting solution；
C, the extracting solution for obtaining step c is concentrated under reduced pressure, and it is 50% that ethanol solution to concentration of alcohol, which is added, and it is small to stand 24
When, filtrate is dried under reduced pressure into dry extract in the case where temperature is 55 DEG C, pressure is -0.08MPa, is ground into fine powder by filtering, spare；
Weigh 10 parts of auxiliary material stearic acid, 10 parts of glycerin monostearate and 5 parts of castor oil are co-located in dry beaker, heating water bath to 60
DEG C, make complete molten, obtains matrix I, it is spare；10 parts of glycerol, 2 parts of ethylparaben and 8 parts of distilled water are set in another beaker, are heated to
60 DEG C, make complete molten, obtains matrix II, it is spare；Under stirring, matrix II is added in matrix I with thread shape, and in water-bath
It keeps constant temperature to be stirred continuously 3 minutes, is removed water-bath and continue stirring to room temperature, then obtained medicinal extract fine powder is added to soft
Cream base Zhi Zhong Subcommittee-to is even, is 6 with sodium dihydrogen phosphate tune pH value, sterilizing, routinely ointment is made in pharmaceutical methods.
Embodiment 12
It is radix system for ointment using 1000ml
A, in parts by weight by 60 parts of the chinaroot greenbrier through having screened, 10 parts of fennelflower seed, 20 parts of coptis root, 50 parts of peppermint, coriander
Sub 20 parts, 20 parts of 10 parts of galla turcica, catechu co-grindings, cross 10 meshes, and the ethanol water reflux that concentration is 40% is added and mentions
It takes 2 times, extraction time is 2 hours, combined extract, then extracting solution is concentrated under reduced pressure, and obtains concentrate；
B, the concentrate for obtaining step a stands 24 hours, and filtering obtains extracting solution；
C, the extracting solution for obtaining step b is concentrated under reduced pressure, and directly depressurizes in the case where temperature is 55 DEG C, pressure is -0.08MPa dry
It is dry to be broken into fine powder at dry extract, then by dry extract, it is spare；Weigh 5 parts of stearic acid, 5 parts of glycerin monostearate, castor oil 2
Part, be co-located in dry beaker, heating water bath makes complete molten to 80 DEG C, obtains matrix I, spare；By 8 parts of glycerol, ethylparaben 2
Part, 12 parts of distilled water set and be heated to 80 DEG C in another beaker, make complete molten, obtain matrix II, it is spare；Under stirring, by matrix
II is added in matrix I with thread shape, and in keeping constant temperature to be stirred continuously 3 minutes in water-bath, is removed water-bath and continue to stir
To room temperature, then that obtained medicinal extract fine powder is added to ointment bases Zhong Subcommittee-to is even, is 6 with sodium bicarbonate tune pH value, sterilizing, routinely
Ointment is made in pharmaceutical methods.
Embodiment 13
It is radix system for gelling agent using 1000ml
A, in parts by weight by 25 parts of the chinaroot greenbrier through having screened, 40 parts of fennelflower seed, 30 parts of coptis root, 40 parts of peppermint, coriander
Sub 40 parts, 40 parts of 80 parts of galla turcica, catechu co-grindings, cross 10 meshes, and 10 times of amount water are added and extract 2 times, extraction time 1.5
Hour, combined extract, then extracting solution is concentrated under reduced pressure, obtain concentrate；
B, the concentrate revolving speed for obtaining step a is 10000 revs/min, is centrifuged 15 minutes, filtering obtains extracting solution；
C, the extracting solution for obtaining step b is concentrated under reduced pressure, and it is 50% that ethanol solution to concentration of alcohol, which is added, and it is small to stand 24
When, filtering, then by filtrate at 55 DEG C of temperature, pressure is to be concentrated under reduced pressure into relative density 1.2 under -0.08MPa, and medicine film tree is added
Rouge -40 stirs equal spoon, and room temperature is swollen 24 hours, and heating water bath makes it dissolve, and when being cooled to 4 DEG C of temperature, the auxiliary material dissolved is added
5 parts of glycerol, 4 parts of benzalkonium bromide, 6 parts of azone, stir equal spoon, are 6 with sodium dihydrogen phosphate tune pH value, sterilizing, routinely pharmacy side
Gel preparation is made in method.
Embodiment 14
It is radix system for gelling agent using 1000ml
A, in parts by weight by 10 parts of the chinaroot greenbrier through having screened, 50 parts of fennelflower seed, 50 parts of coptis root, 20 parts of peppermint, coriander
Sub 40 parts, 5 parts of 30 parts of galla turcica, catechu co-grindings, cross 20 meshes, and addition concentration is 60% ethanol water refluxing extraction 3
Secondary, extraction time is 1 hour, combined extract, then extracting solution is concentrated under reduced pressure into thick paste under temperature 60 C；
B, the thick paste that step a is obtained is dried under reduced pressure into dry extract in the case where temperature is 55 DEG C, pressure is -0.08MPa, then will
Dry extract is broken into fine powder, spare；5 parts of auxiliary material Kappa nurse are uniformly spread on the distillation water surface, stirring makes sufficiently to be swollen, spare；
Obtained extract powder and 3 parts of auxiliary material ethylparaben are dissolved with ethyl alcohol, 6 parts of azone, 6 parts of propylene glycol mixings is added, adds
Kappa nurse reserve liquid, it is stirring while adding, it stirs evenly, then it is 5.5 that sodium bicarbonate tune pH value, which is slowly added dropwise, it is stirring while adding, it stirs
It mixes uniformly, routinely gelling agent is made in pharmaceutical methods.
Embodiment 15
It is radix system for gelling agent using 1000ml
A, in parts by weight by 40 parts of the chinaroot greenbrier through having screened, 40 parts of fennelflower seed, 20 parts of coptis root, 10 parts of peppermint, coriander
Sub 50 parts, 50 parts of 5 parts of galla turcica, catechu co-grindings, cross 10 meshes, and addition concentration is 50% ethanol water refluxing extraction 3
Secondary, extraction time is 1 hour, combined extract, then extracting solution is concentrated under reduced pressure into thick paste under temperature 60 C；
B, the thick paste that step a is obtained is dried under reduced pressure into dry extract in the case where temperature is 60 DEG C, pressure is -0.08MPa, then will
Dry extract is broken into fine powder, spare；6 parts of auxiliary material sodium carboxymethylcellulose are uniformly spread on the distillation water surface, stirring makes sufficiently molten
It is swollen, it is spare；Obtained cream powder and 4 parts of auxiliary material ethylparaben are dissolved with ethyl alcohol, 8 parts of azone, 6 parts of propylene glycol mixings is added,
Sodium carboxymethylcellulose reserve liquid is added, it is stirring while adding, it stirs evenly, then it is 7 that sodium citrate tune pH value, which is slowly added dropwise, side
Edged stirring, stirs evenly, routinely gel preparation is made in pharmaceutical methods.
Embodiment 16
Rhinitis compound medicine evaluation of effect of the present invention:
1.1 test medicines:
1.1.1 test sample, the present invention described in drug, by Xinjiang medicament research department of uighur medicine research institute prepare；
1.1.2 positive control drug: nose leads to nasal drop；
1.2 experimental animals and feed: kunming mice, Wistar rat, rabbit, male and female dual-purpose；SPF grades of size mouse feeds,
Rabbit feed；
1.3 experimental materials: dimethylbenzene, trinitro-chlorobenzene, ethyl alcohol, acetone, sodium sulphate, Propionibacterium, egg white, ivens
Indigo plant, physiological saline, formaldehyde；
1.4 instrument and equipments: BP3100P Sai Duolisi electronic balance (German sartorius company), the ultraviolet wind of Cintra20
Light photometer (Australian GE company)；
1.5 Animal Lab. conditions: animal house entire area 120m2, wherein mouse animal experiment room area 25m2, experiment
Room air timing exhaust Air Cleaning, 12h/12h manual control light and shade alternating, humidity 40-60%, 20-23 DEG C of temperature control；
2 dose designs:
Corresponding experimental animal dosage is converted to according to prescription and quantity；Low dose group (0.1g/ of the present invention
Ml), middle dose group (0.2g/ml) of the present invention, high dose group of the present invention (0.3g/ml)；
3 experimental methods:
The influence of 3.1 paraxylene cause mouse ear swelling:
Take mouse, male and female dual-purpose, described in the present invention for being randomly divided into model control group, positive drug control group and three dosage
Dimethylbenzene is uniformly applied to mouse right ear after the last administration by setting dosage in mouse right ear exterior feature local administration 3 days by medicine group
Wide two sides causes inflammation, is compared with left ear；Cervical dislocation puts to death mouse after 30min, and in left and right, ear antimere lays round ear respectively
Piece, weighing calculate swelling and swelling inhibiting rate；
The influence that 3.2 paraxylene cause mouse skin capillary permeability to increase:
Take mouse, male and female dual-purpose, described in the present invention for being randomly divided into model control group, positive drug control group and three dosage
Medicine group, according to dosage local administration (smear in four times, every 15 minutes apply primary) on the position skin of unhairing of mouse web portion center,
Model group applies equivalent excipient；Medical fluid is wiped after 1h, in 0.5% Evans blue normal saline solution 0.1ml/ of tail vein injection
10g drips upper dimethylbenzene 0.03ml/ only in coating position immediately, and cervical dislocation is put to death after 20min, peels the skin for locus coeruleus position occur
Skin is put into tool plug test tube after shredding, and adds acetone-sodium sulphate extracting solution 10ml, sets dark place placement, daily shake 2-3 times, and three
2000rpm/min is centrifuged 10min in the future, takes supernatant, and using acetone-sodium sulphate liquid as blank, light absorption value is surveyed at 590nm.Meter
Calculate the inhibiting rate that drug oozes out inflammatory；
The therapeutic effect of 3.3 pairs of rat allergic rhinitis models:
Rat is taken, male and female dual-purpose is randomly divided into model control group, positive drug control group, former preparations. Control group and three agent
Medicine group described in the present invention of amount, each group according to dosage intranasal administration, the isometric physiological saline of model control group collunarium, daily 1
It is secondary.Taking ovalbumin 0.3mg to be aided with aluminium hydroxide 30mg simultaneously is that adjuvant adds physiological saline to be prepared into suspension, gives rat abdominal cavity
Injection, the next day inject 1 time, it is co-injection 7 times big as basic sensitization, then with the attack of 0.5% ovalbumin normal saline suspension
Mouse nasal cavity, every side 0.05ml, one time a day, totally 7 times；Modeling animal is in last nasal cavity sensitization 30min, using " quantization superposition note
Point-score " scores to rat behavior index, is superimposed total score >=5 as modeling success, standards of grading: flipping nasal surface for several times, can
See that nasal mucus is a small amount of, sneeze number 1-3 times, 1 point；Scratching nasal surface is multiple, and tears are crossed the centre line, sneeze number 4-9 times, and 2 points；Rub nose everywhere
Face observes 30min after attack every time, records standards of grading；
3.4 pairs of trinitro-chlorobenzenes (PC) cause the influence of mouse delayed allergy:
Mouse is taken, male and female dual-purpose is randomly divided into Normal group, model control group, positive drug control group, former preparations. Control
Medicine group described in the present invention of the group with three dosage, is according to dosage administered 7 days in mouse right ear exterior feature local continuous, is administered the 2nd day small
The depilation of mouse abdomen 1 hour after administration in the 3rd day, is applied to depilation position with 2% couple of trinitro-chlorobenzene ethanol solution 0.05ml, every
Day is primary with method reinforcing sensitization, 1 hour after administration in the 7th day, is applied to 0.5% couple of trinitro-chlorobenzene olive oil solution 0.02ml
Mouse right ear two sides is attacked, and cervical dislocation puts to death mouse after 24 hours, and in left and right, ear antimere lays round auricle respectively,
Weighing, calculates left and right auricle weight difference to reflect delayed allergy intensity, and calculate swelling inhibiting rate；
4 experimental results:
The experimental results showed that each dosage group paraxylene of the present invention causes mouse ear swelling to have significantly compared with model group
Inhibiting effect (P < 0.05 or P < 0.01), and act on be in dose-dependence, be shown in Table 1；
The influence of 1 paraxylene of table cause mouse ear swellingN=10
Note: compared with model group,**P < 0.01,*P < 0.05；
The experimental results showed that each dosage group paraxylene of the present invention causes mouse skin capillary logical compared with model group
Permeability, which increases, significant inhibiting effect (P < 0.01), and acting on is in dose-dependence, is shown in Table 2；
The influence that 2 paraxylene of table causes mouse skin capillary permeability to increaseN=10
Note: compared with model group,**P < 0.01
The experimental results showed that each dosage group of the present invention has rat allergic rhinitis model certain compared with model group
Therapeutic effect (P < 0.05 or P < 0.01) can reduce the scoring of rat anaphylaxis model behavior, be shown in Table 3；
Therapeutic effect of the table 3 to rat allergic rhinitis modelN=10
Note: compared with model group,**P < 0.01,*P < 0.05；
The experimental results showed that each dosage group of the present invention causes mouse delayed to trinitro-chlorobenzene (PC) compared with model group
Hypersensitivity intensity has significant inhibiting effect (P < 0.05 or P < 0.01), and acting on is in dose-dependence, is shown in Table 4；
Table 4 causes the influence of mouse delayed allergy to trinitro-chlorobenzene (PC)N=10
Note: compared with model group,**P < 0.01,*P < 0.05.
To sum up, rhinitis compound medicine of the present invention has treatment acute rhinitis or/and rhinitis chronic and allergic rhinitis
Effect in drug.
Claims (3)
1. a kind of compound medicine for treating rhinitis, it is characterised in that the compound medicine using 1000ml as radix, in parts by weight for
5-80 parts of chinaroot greenbrier, 5-60 parts of fennelflower seed, 5-60 parts of coptis root, 5-60 parts of peppermint, 5-60 parts of ceriander seed, 5-80 parts of galla turcica, youngster
5-60 parts of tea, auxiliary material is glycerol, sodium carboxymethylcellulose, benzalkonium bromide, ethylparaben, sodium benzoate, carbomer, tristearin
Acid, glycerin monostearate, castor oil, sodium citrate, sodium dihydrogen phosphate, sodium bicarbonate, azone, propylene glycol, borax or sweet dew
5-37 parts of alcohol are made nasal drop, collunarium, spray, ointment or gel preparation.
2. a kind of preparation method of compound medicine for treating rhinitis according to claim 1, it is characterised in that press following step
It is rapid to carry out:
It a, will be in parts by weight 5-80 parts of chinaroot greenbrier, 5-60 parts of fennelflower seed, 5-60 parts of coptis root, peppermint using 1000ml as radix
5-60 parts, 5-60 parts of ceriander seed, 5-80 parts of galla turcica, 5-60 parts of catechu carry out being crushed to 10-20 mesh, are uniformly mixed, and 4- is added
20 times of water or concentration is ethanol water refluxing extraction 1-4 times of 10-95%, and the time is 1-3 hours, combined extract, then will
Extracting solution is concentrated under reduced pressure, and obtains concentrate；
B, the concentrate for obtaining step a is centrifuged 5-20 minutes, and centrifugal rotational speed is 5000-20000 revs/min；Or it is with concentration
The ethanol solution of 30-80% precipitates；Or stand, filtering obtains extracting solution；
C, it is glycerol, sodium carboxymethylcellulose, benzalkonium bromide, carbomer, nipalgin that auxiliary material, which is added, in the extracting solution for obtaining step b
Ethyl ester, sodium benzoate, sodium citrate, sodium dihydrogen phosphate, sodium bicarbonate, borax or 5-20 parts of mannitol are uniformly mixed, and adjust pH
Value is 5.5-7.5, and with deionized water constant volume, after sterilizing, routinely nasal drop, collunarium, spray is made in pharmaceutical methods；
Or step b is obtained into extracting solution and is concentrated under reduced pressure, it is 50% that ethanol solution to concentration of alcohol, which is added, 24 hours are stood, filtering,
Filtrate is dried under reduced pressure into dry extract in the case where temperature is 55 DEG C, pressure is -0.08MPa, addition auxiliary material is glycerol, carboxymethyl cellulose
Plain sodium, benzalkonium bromide, ethylparaben, carbomer, stearic acid, glycerin monostearate, castor oil, sodium dihydrogen phosphate or carbonic acid
20-37 parts of hydrogen sodium are uniformly mixed, and adjustings pH value is 5.5-7.5, with deionized water constant volume, after sterilizing, and routinely pharmaceutical methods system
At ointment or gel preparation；
Or step b is obtained into extracting solution and is concentrated under reduced pressure, it is directly dried under reduced pressure into the case where temperature is 55 DEG C, pressure is -0.08MPa dry
Medicinal extract, addition auxiliary material is glycerol, sodium carboxymethylcellulose, benzalkonium bromide, ethylparaben, carbomer, azone, propylene glycol, hard
Resin acid, glycerin monostearate, castor oil, sodium citrate, sodium dihydrogen phosphate or 20-37 parts of sodium bicarbonate are uniformly mixed, and are adjusted
PH value is 5.5-7.5, and with deionized water constant volume, after sterilizing, routinely ointment or gel preparation is made in pharmaceutical methods.
3. a kind of compound medicine for treating rhinitis as defined in claim 1 is in preparation treatment acute rhinitis or/and chronic
Purposes in rhinitis and allergic rhinitis drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811485928.8A CN109288997A (en) | 2018-12-06 | 2018-12-06 | A kind of compound medicine and its preparation method and application for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811485928.8A CN109288997A (en) | 2018-12-06 | 2018-12-06 | A kind of compound medicine and its preparation method and application for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109288997A true CN109288997A (en) | 2019-02-01 |
Family
ID=65142677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811485928.8A Pending CN109288997A (en) | 2018-12-06 | 2018-12-06 | A kind of compound medicine and its preparation method and application for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109288997A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883676A (en) * | 2006-05-30 | 2006-12-27 | 斯拉甫·艾白 | Preparation for treating rhinitis |
| CN102861116A (en) * | 2012-10-18 | 2013-01-09 | 中国科学院新疆理化技术研究所 | Method for preparing pericarpium granati polyphenol gel for treating gynecological inflammation |
| CN107412331A (en) * | 2017-09-14 | 2017-12-01 | 新疆维吾尔自治区药物研究所 | Nasal formulations for treating rhinitis and its preparation method and application |
-
2018
- 2018-12-06 CN CN201811485928.8A patent/CN109288997A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883676A (en) * | 2006-05-30 | 2006-12-27 | 斯拉甫·艾白 | Preparation for treating rhinitis |
| CN102861116A (en) * | 2012-10-18 | 2013-01-09 | 中国科学院新疆理化技术研究所 | Method for preparing pericarpium granati polyphenol gel for treating gynecological inflammation |
| CN107412331A (en) * | 2017-09-14 | 2017-12-01 | 新疆维吾尔自治区药物研究所 | Nasal formulations for treating rhinitis and its preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| 周丕文,等: "HPLC法测定清涩比黑马尔江散中没食子酸的含量", 《新疆中医药》 * |
| 蔡向红编著: "《单味中药补养速查》", 31 March 2017, 安徽科学技术出版社 * |
| 黄煌，等主编: "《名中医方药传真》", 31 July 2018, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107412331B (en) | Nasal preparation for treating rhinitis and preparation method and application thereof | |
| WO2013102410A1 (en) | Oral liquid for treating allergic cough | |
| CN107898816A (en) | Eye medicinal preparation and its application | |
| CN109294835A (en) | A kind of Chinese medicament healthcare wine formula of anti-aging | |
| CN102335274B (en) | Chinese medicinal composition for preventing and treating inflammation-related diseases | |
| CN104547934A (en) | Medicine preparation for treating electric ophthalmia and preparation method thereof | |
| CN104116979A (en) | Medicinal liquor for treating phthisis and preparation method thereof | |
| CN104548008B (en) | A kind of pharmaceutical composition prevented and/or treat allergic skin diseases and preparation method thereof | |
| CN108523121A (en) | A kind of functional food and preparation method thereof of anti-haze clearing lung-heat | |
| CN109288997A (en) | A kind of compound medicine and its preparation method and application for treating rhinitis | |
| CN114558049B (en) | Traditional Chinese medicine prescription for treating chronic obstructive pulmonary disease in stationary phase series and application thereof | |
| CN107929366A (en) | A kind of Chinese medicine composition for treating allergic rhinitis | |
| CN104666823B (en) | A kind of regulation immunity, pharmaceutical composition of anti-aging and preparation method thereof | |
| CN105012279B (en) | Composition containing nonyl alcohol and its in application pharmaceutically | |
| CN105343274A (en) | Drug combination having inflammation diminishing and cough relieving functions | |
| CN102641480B (en) | Traditional Chinese medicine composite used for treating microcirculation disturbance and preparation method thereof | |
| CN114470110B (en) | Anti-rhinitis traditional Chinese medicine composition with pain relieving effect | |
| CN109528708A (en) | Application of the Kaempferol in preparation treatment rhinitis drug | |
| CN115040600B (en) | Traditional Chinese medicine composition for treating scalp psoriasis | |
| CN102727834B (en) | Traditional Chinese medicine composition for treating migraine, and preparation method and application thereof | |
| CN102670781A (en) | Hand-protecting snake oil liniment | |
| CN108653554B (en) | A Chinese medicinal composition for treating respiratory system diseases, and its preparation method | |
| CN108465009A (en) | Saorilao removing heat from the lung to relieve cough capsule particle fluidized bed coating technique research and its clinical application | |
| WO2023024632A1 (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method therefor | |
| CN104547357B (en) | A kind of Chinese medicine compound prescription that treating allergic rhinitis, tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190201 |
|
| RJ01 | Rejection of invention patent application after publication |